In a groundbreaking presentation at the European Association for the Study of the Liver (EASL) Annual Congress in Shanghai on May 16, 2025, CureGene Pharmaceuticals unveiled a pioneering liver-targeted THR-β prodrug. This innovative drug, activated through hydrolysis, is the first of its kind and has shown a unique dual benefit of reducing fat and preserving muscle. This development marks a significant advancement in the field of liver-targeted therapies.